Chimeron Bio Establishes Accessible Medicines Advisory Board (AMAB) and Appoints Mr. Sven Otto Littorin, Former Minister of Employment of Sweden, to Lead It

PHILADELPHIA–(BUSINESS WIRE)–Chimeron Bio, an RNA company pioneering a novel class of mRNA-based vaccines and therapeutics is pleased to announce the appointment of Mr. Sven Otto Littorin as Head of its new Accessible Medicines Advisory Board (AMAB). AMAB is established to develop and execute strategies to make medicines developed by Chimeron Bio accessible to countries and its citizens worldwide. This board, which will consist of accomplished world body members and distinguished scholars, will work with leading global and philanthropic organizations as well as government bodies to facilitate easy access to Chimeron’s cutting-edge mRNA therapeutics and vaccines.

A successful entrepreneur and politician, Mr. Littorin was the former Minister for Employment of Sweden and President of the European Council of Ministers (EPSCO) during the Swedish Presidency in 2009. He brings decades of unparalleled experience in delivering results in difficult environments, forging new markets, and spearheading innovative development in new economies to the team. Amongst other notable roles, Mr. Littorin has been an advisor to the Ministry of Labor and Social Development and to the Human Resources Development Fund (HRDF) in Saudi Arabia where he assisted in developing and implementing a New Labor Market Strategy, together with the World Bank and other international organizations. He is the co-founder of the Innovation for Jobs Summits, a body focused on bringing together world leaders to discuss employment during continued innovation.

“At Chimeron Bio, we are using our novel patent-protected RNA technology to develop therapeutics and vaccines that are innovative and transformational. As an example, our COVID-19 vaccine is being developed as a low dose product, which is easy and inexpensive to make and can be stored in regular refrigerators for many months. Such novel and practical medicine needs to be made available to all. Therefore, a team focused on this aspect of Chimeron’s corporate responsibility is important to us, and I am thrilled to see Sven lead this effort,” said Dr. Jolly Mazumdar, CEO of the Company.

“Chimeron Bio’s goal, by virtue of its technology features, is to be a preferred partner for developing vaccines and therapeutics. With Sven’s leadership and experience in global community outreach, and his demonstrated ability to forge partnerships with governments and world bodies, we feel confident he will successfully lead Chimeron Bio’s effort to have an international presence and be a prominent player in vaccine development,” said Dr. Afshin Safavi, Chairman of the Board.

“It is indeed an honor to lead Chimeron’s AMAB. Chimeron has an innovative platform to develop RNA vaccines and drugs with infrastructure-friendly features that include ease of manufacturing and globally compatible supply and distribution chains. These critical elements are key to making drugs or vaccines accessible to all of us, regardless of economic situation. With my understanding and experience in global environments, both political and business, I want to move this technology beyond its current reach and help people access this new generation of vaccines and therapeutics now and in the future,” said Mr. Littorin.

About Chimeron Bio

Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA drugs and vaccines for various diseases. The company is using its proprietary ChaESAR^TM platform to develop a pipeline in oncology, rare genetic disorders, and infectious diseases. It is developing two COVID-19 vaccine candidates each with its unique mechanism of action. The candidates have shown promise in early preclinical safety assessment and are under further development. For more information, visit www.chimeron.com.

Contacts

Chimeron Bio

Jolly Mazumdar, Ph.D.

[email protected]